The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Personalized cancer treatment with ER inhibition strategies for NSCLC
Robert Hsu, MD, Keck School of Medicine, USC, Los Angeles, CA, discusses the future of personalized cancer treatment in non-small cell lung cancer (NSCLC), highlighting advancements in understanding EGFR and KRAS G12C mutations in relation to estrogen receptors (ER), specifically ER-alpha (ESR1) and ER-beta (ESR2). For example, in breast cancer, ESR1 inhibitors such as FDA-approved elacestrant are already established. This prompts exploring the potential of combining ESR1 inhibitors with existing tyrosine kinase inhibitors such as osimertinib in the clinic, to leverage synergistic effects and potentially improving outcomes for patients with NSCLC. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – DAVA Oncology; The Dedham Group
Consulting or Advisory Role – Takeda; Targeted Oncology
